KR950000151A - 의약조성물 - Google Patents
의약조성물 Download PDFInfo
- Publication number
- KR950000151A KR950000151A KR1019940013383A KR19940013383A KR950000151A KR 950000151 A KR950000151 A KR 950000151A KR 1019940013383 A KR1019940013383 A KR 1019940013383A KR 19940013383 A KR19940013383 A KR 19940013383A KR 950000151 A KR950000151 A KR 950000151A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- hydroxypropyl cellulose
- weight
- oral absorption
- medicinal composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
(-)-(6R,7R)-7-[(Z)-2-(2-아미노티아졸-4-일)-2-메톡시이미노아세트아미드]-3-[(Z)-2-(4-메틸티아졸-5-일)에티닐]-8-옥소-5-티아-1-아자비시크로[4.2.0]옥토-2-엔-2-카르본산 2,2-디메틸프로피오닐옥시메틸에스텔(이하 세프디트렌피복실이라 칭함)의 쓴맛이 적은 경구 흡수개량 의약조성물을 제공한다. 세프디트렌피복실과 히드록시프로필셀루로즈를 함유시킴으로써, 경구흡수성이 우수한 쓴맛이 적은 적은 의약조성물이 얻어졌다. 세프디트렌피복실량에 대해 히드록시프로필셀루로즈를 0.4배 중량이상, 바람직하기로는 0.8~4배 중량 제제중에 배합한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명 조성물 및 본 발명의 조성물의 용출곡선(n=3의 평균)을 표시, 제2도는 본 발명 조성물을 물에 현탁시켰을때의 현탁입자의 평균입경과 히드록시프로필셀루로즈/세프지트렌피복실의 배합비율의 관계를 표시, 제3도는 본 발명 조성물 및 본 발명의 조성물을 비글견(犬)에 경구 투여했을때의 혈장중 세프지트렌농도추이(n=8의 평균)을 표시.
Claims (2)
- 세프디트렌피복실과 히드록실프로필셀루로즈를 함유하는 것을 특징으로 하는 의약조성물.
- 제1항에 있어서, 세프디트렌피복실에 대한 히드록시프로필셀루로즈의 배합비가 0.4~4(중량비)인 의약조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP93-144585 | 1993-06-16 | ||
JP5144585A JPH0717866A (ja) | 1993-06-16 | 1993-06-16 | 医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950000151A true KR950000151A (ko) | 1995-01-03 |
Family
ID=15365534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940013383A KR950000151A (ko) | 1993-06-16 | 1994-06-14 | 의약조성물 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0629404A1 (ko) |
JP (1) | JPH0717866A (ko) |
KR (1) | KR950000151A (ko) |
CN (1) | CN1105240A (ko) |
CA (1) | CA2125936A1 (ko) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
AR004014A1 (es) * | 1995-10-13 | 1998-09-30 | Meiji Seika Kaisha | Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion |
PL194097B1 (pl) * | 1998-01-07 | 2007-04-30 | Meiji Seika Kaisha | Kompozycja zawierająca krystalograficznie trwałą amorficzną cefalosporynę i sposób jej wytwarzania |
JP4827367B2 (ja) * | 2000-11-21 | 2011-11-30 | 杏林製薬株式会社 | ドライシロップ剤 |
CA2449002C (en) * | 2001-05-29 | 2011-08-16 | Tap Pharmaceutical Products Inc. | Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin |
WO2003097102A1 (fr) * | 2002-05-22 | 2003-11-27 | Shionogi & Co., Ltd. | Preparation pharmaceutique dans laquelle la propriete de dissolution d'un medicament faiblement soluble dans l'eau est amelioree |
WO2004030673A1 (ja) | 2002-10-02 | 2004-04-15 | Meiji Seika Kaisha, Ltd. | 経口吸収性が改善された抗菌性医薬組成物 |
JP4640821B2 (ja) * | 2003-07-24 | 2011-03-02 | 塩野義製薬株式会社 | 難水溶性薬物を含むドライシロップ剤 |
ATE539738T1 (de) * | 2003-10-08 | 2012-01-15 | Meiji Seika Pharma Co Ltd | Nichtkristalline antibakterielle zusammensetzung mit cefditoren-pivoxil |
JP2005162696A (ja) * | 2003-12-04 | 2005-06-23 | Nichiko Pharmaceutical Co Ltd | 溶出性に優れたセフジトレンピボキシル製剤 |
KR20070040389A (ko) * | 2004-08-10 | 2007-04-16 | 아지노모토 가부시키가이샤 | 쓴 맛이 감소된 나테글리니드 함유 제제 |
WO2008057058A1 (en) * | 2006-11-10 | 2008-05-15 | Nobel Ilac Sanayii Ve Ticaret As | Oral pharmaceutical compositions |
WO2012010938A2 (en) * | 2010-07-23 | 2012-01-26 | Lupin Limited | Pharmaceutical compositions of cefditoren pivoxil |
CN102846570B (zh) * | 2012-09-13 | 2013-10-23 | 山东罗欣药业股份有限公司 | 一种头孢妥仑匹酯组合物片剂及其制备方法 |
KR101561963B1 (ko) * | 2013-05-23 | 2015-10-22 | 영진약품공업 주식회사 | 세프디토렌 피복실의 신규 결정 형태 및 이의 제조 방법 |
EP3244879A1 (en) | 2015-01-16 | 2017-11-22 | Ögün, Yusuf Toktamis | Cefditoren pivoxil compositions with improved stability and production methods thereof |
CN110251467A (zh) * | 2019-06-26 | 2019-09-20 | 北京济美堂医药研究有限公司 | 一种无定形态头孢妥仑匹酯组合物的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0678234B2 (ja) * | 1988-04-19 | 1994-10-05 | 明治製菓株式会社 | 経口投与用抗菌組成物 |
-
1993
- 1993-06-16 JP JP5144585A patent/JPH0717866A/ja active Pending
-
1994
- 1994-06-14 KR KR1019940013383A patent/KR950000151A/ko not_active Application Discontinuation
- 1994-06-15 CA CA002125936A patent/CA2125936A1/en not_active Abandoned
- 1994-06-15 EP EP94109216A patent/EP0629404A1/en not_active Withdrawn
- 1994-06-16 CN CN94108907A patent/CN1105240A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0629404A1 (en) | 1994-12-21 |
CA2125936A1 (en) | 1994-12-17 |
JPH0717866A (ja) | 1995-01-20 |
CN1105240A (zh) | 1995-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950000151A (ko) | 의약조성물 | |
US4665081A (en) | Solid nifedipine preparations and a process for preparing same | |
JP2916152B2 (ja) | 薬物放出速度調節型製剤 | |
IE881452L (en) | Pharmaceutical composition | |
Klepser et al. | Clinical pharmacokinetics of newer cephalosporins | |
WO2004060351A3 (en) | Pharmaceutical formulation with an insoluble active agent for pulmonary administration | |
US4620974A (en) | Pharmaceutical composition containing a liquid lubricant | |
JPH0399012A (ja) | 経口投与可能なn―アセチル―システイン含有製剤 | |
WO2008057058A1 (en) | Oral pharmaceutical compositions | |
CA1334934C (en) | Antibacterial composition for oral administration | |
CN104644610A (zh) | 一种头孢氨苄胶囊 | |
CA2388325A1 (en) | Ciclesonide-containing aqueous pharmaceutical composition | |
TW201004625A (en) | A fine grain agent having improved water-suspensibility | |
CZ138595A3 (en) | Easily re-dispersible and chemically stable pharmaceutical preparation containing cefixim | |
Bryskier et al. | The pharmacokinetics of cefodizime following intravenous and intramuscular administration of a single dose of 1.0 g | |
EP0867181A1 (en) | Nasal melatonin composition | |
KR870010082A (ko) | 구아르(guar) 분말 | |
Rattie et al. | Acetaminophen prodrugs III: Hydrolysis of carbonate and carboxylic acid esters in aqueous buffers | |
JP4841130B2 (ja) | 安定化されたビタミン製剤 | |
GB1479655A (en) | Antibiotic preparations | |
US5525596A (en) | Absorption enhancer/solubilizer combination for improved bioavailability of a zwitterionic compound | |
US4777048A (en) | Pharmaceutical composition containing a liquid lubricant | |
JP2006219462A (ja) | 経口製剤用粒子 | |
US4406888A (en) | Aqueous micellar solutions of levonantradol and N-methyllevonantradol and lyophilic forms thereof for reconstitution | |
NZ212763A (en) | Ph-3- (1-pyridiniummethyl)-3-cephem-4- carboxylate pentahydrate and amorphous lactose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |